Safety and Immunogenicity of Malaria Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".
Deadline for manuscript submissions: closed (10 October 2023) | Viewed by 214
Special Issue Editors
Interests: vaccines; malaria; monoclonal antibodies; protein design and engineering; bioassays; structural vaccinology
Interests: immunology; T cell & B cell biology;generation and maintenance of memory
Special Issue Information
Dear Colleagues,
Malaria affects one-third of the world's population and is responsible for up to half a million deaths worldwide per year. Plasmodium falciparum and Plasmodium vivax are parasites that cause severe malaria and related deaths. Malaria morbidity and mortality are on the rise, and emerging drug resistance is intensifying the need for alternative treatment strategies and preventative measures. Over time, natural infection leads to robust immunity against malaria parasite infection, suggesting that a vaccine inducing immune responses in a similar way could effectively stop malaria pathogenesis. The current malaria vaccine, RTS,S/AS01, has shown significant short-term efficacy, but there is an urgent need to improve durable vaccine efficacy against clinical malaria. Therefore, it is necessary to identify essential and strain-transcending vaccine immunogens that elicit potent neutralizing antibody responses and are safe and tolerable. Vaccine adjuvants are likely to be required for immunogens, and these adjuvants must show acceptable safety and the ability to enhance cellular and humoral immunity. This emphasizes the necessity of investigating the safety and immunogenicity of malaria vaccine immunogens with and without adjuvants in order to develop a safe and effective malaria vaccine.
In this Special Issue, we welcome original research articles and reviews that describe (but are not limited to) the development of novel malaria vaccine candidates and assessments of their safety, immunogenicity, and efficacy in preclinical and clinical studies.
We look forward to receiving your contributions.
Dr. Palak Patel
Dr. Hardik Patel
Dr. Ramesh Chingle
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- malaria
- Plasmodium parasites
- antigens
- immunogens
- adjuvants
- antibody responses
- safety and immunogenicity
- vaccine efficacy
